Q0174 HCPCS Level II Code: Thiethylperazine maleate, 10 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a…
HCPCS Level II code, maintained by CMS. Not a CPT code: CPT (HCPCS Level I) is a separate AMA code set that MedCoder does not publish. About HCPCS Level II
Compare with another code for Q0174Check this code on a claim
Code status: Not valid. Removed from HCPCS Level II: not valid for dates of service on or after January 1, 2026.
Medicare Coverage & Payment
- CMS short descriptor: Thiethylperazine maleate10mg
- Medicare coverage: Special coverage instructions apply (CMS coverage code D)
- Payment category: Drugs (pricing indicator 51)
- BETOS: O1D — Chemotherapy
- Last CMS action effective: January 1, 2026
- Terminated: December 31, 2025
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Code Set: Removed from the code set — not valid on or after January 1, 2026.
Coding context
Guidelines, coding notes, decision aids, relationships (with MS-DRG and CCSR classification), hierarchy, HCC, coverage and the context map: what a coder reaches for after the core. Each section names whether it is official source data, a MedCoder-derived relationship or MedCoder editorial.
Contextual Map
Every relationship of Q0174 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (21)
- Q0111 — Wet mounts, including preparations of vaginal, cervical or skin specimens[Sibling]— CMS HCPCS Level II code set
- Q0112 — All potassium hydroxide (koh) preparations[Sibling]— CMS HCPCS Level II code set
- Q0113 — Pinworm examinations[Sibling]— CMS HCPCS Level II code set
- Q0114 — Fern test[Sibling]— CMS HCPCS Level II code set
- Q0115 — Post-coital direct, qualitative examinations of vaginal or cervical mucous[Sibling]— CMS HCPCS Level II code set
- Q0138 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)[Sibling]— CMS HCPCS Level II code set
- Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)[Sibling]— CMS HCPCS Level II code set
- Q0144 — Azithromycin dihydrate, oral, capsules/powder, 1 gram[Sibling]— CMS HCPCS Level II code set
- and 13 more
Change history (2)
- January 1, 2026 — Removed from the code set [Change history]— CMS release files (code change ledger)
- and 1 more
Reference
Index terms and tables, published questions and FAQ, every source behind this page with its release and checksum, the date-of-service check and the complete change history.
Sources for this page
Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.
- Code, descriptors, coverage and pricing attributes Official source data
- CMS HCPCS Alpha-Numeric (ANWEB) release — October 2026 quarterly update Release, file and checksum · Publisher’s page
- Change history and date-of-service validity Official source data
- CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page
- Comparisons, relationships and the contextual map MedCoder-derived relationship
- Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears
- Summary and FAQ answers MedCoder editorial explanation
- Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.
Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources
Labels on this page: Official source data · MedCoder-derived relationship · MedCoder editorial explanation. How to read the labels · All data sources and release dates · CMS coding rules
Cite this page
Reference this page in a research guide, syllabus or article. The release is included because code content changes each year.
MedCoder.ai. "Q0174 — Thiethylperazine maleate, 10 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen." HCPCS Level II October 2026. https://medcoder.ai/hcpcs/code/q0174-thiethylperazine-maleate-10-mg-oral-fda-approved-prescription-anti-emetic
Change history
- January 1, 2026Removed from the code setThiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenHCPCS 2026 changes
- April 1, 1998Added to the code setThiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenHCPCS 1998 changes
Nearest Codes in This Family
Official HCPCS Level II classifications closest to Q0174 in its code family, with their registry titles.
- Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a…
- Q0164 — Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a…
- Q0166 — Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a…
- Q0167 — Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour…
- Q0169 — Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to…
- Q0173 — Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to…
- Q0175 — Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour…
- Q0177 — Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48…
- Q0180 — Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24…
- Q0181 — Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour…